RankingsPricing
  1. US-listed companies
  2. PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc.PMCB

Market cap
$16.94M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Apr 30,
2012		Apr 30,
2013		Apr 30,
2014		Apr 30,
2015		Apr 30,
2016		Apr 30,
2017		Apr 30,
2018		Apr 30,
2019		Apr 30,
2020		Apr 30,
2021		Apr 30,
2022		Apr 30,
2023
Net loss-1,899,312-1,598,102-27,254,020-10,854,509-6,063,784-4,443,685-6,828,841-4,067,228-3,826,888-3,551,236-4,239,161-4,315,993
Other non-cash expenses-----------171,744
Stock issued for services--181491,684107,500309,881316,539473,14170,32634,8462,278
Stock issued for compensation2984,696-735,189405,080420,480580,360293,329368,650194,26133,1467,334
Stock-based compensation - options---5788,770597,400945,078412,349379,375176,56844,810638,072
Decrease in prepaid expenses and other current assets----------21,04113,509
Decrease in other assets----------316-
Increase (decrease) in accounts payable173,82597,708-59,191308,654-160,69029,591-12,979-230,73663,958-13,58133,100-242,948
Decrease in accrued expenses192,654153,9571,503-18,096127,96363,01876,899311,919208,025-201,680-2,703-40,709
Net cash used in operating activities-259,289-390,426-----5,079,395-2,877,912-2,338,373-3,330,889-4,117,319-3,793,731
Net cash used in investing activities-871,730-646,750----------
Payment of insurance financing loan----------50,805-
Repurchase of common stock-----------14
Proceeds from exercise of warrants-----------880
Proceeds from sale of common stock, net of issuance costs21,00019445323587-
Net cash provided by (used) in financing activities11----323587-13,559,743
Effect of currency rate exchange on cash and cash equivalents------------7,246
Net increase (decrease) in cash and cash equivalents---------183-17,360,720
Cash paid during the years for income taxes------8008008008001,600-
Cash paid during the years for interest expense--------4532,267509-
Non-cash equity issuance costs----------34-